2023
Wong C, Gregory JM, Liao J, … and 33 others. Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus. BMJ Open 2023; 13:e064169 [See here for associated preprint].
Pattle SB, O’Shaughnessy J, Kantelberg O, Rifai OM, Pate J, Nellany K, Hays N, Arends MJ, Horrocks MH, Waldron FM, Gregory JM. pTDP-43 aggregates accumulate in non-central nervous system tissues prior to symptom onset in amyotrophic lateral sclerosis: a case series linking archival surgical biopsies with clinical phenotypic data. Journal of Pathology: Clinical Research 2022; 9: 44-55 [see here for associated preprint].
Rifai OM, O’Shaughnessy J, Dando OR, Munro AF, Sewell MDE, Abrahams S, Waldron FM, Sibley CR, Gregory JM. Distinct neuroinflammatory signatures exist across genetic and sporadic ALS cohorts. bioRxiv 2023; 2023.01.19.524561.
2022
Leighton DJ, Ansari M, Newton J, Parry D, Cleary E, Colville S, Stephenson L, Larraz J, Johnson M, Beswick E, Wong M, Gregory JM, Carod Artal J, Davenport R, Duncan C, Morrison I, Smith C, Swingler R, Deary IJ, Porteous M, Aitman TJ, Chandran S, Gorrie GH, Pal S, the Lothian Birth Cohorts Group & and the CARE-MND Consortium. Genotype–phenotype characterisation of long survivors with motor neuron disease in Scotland. Journal of Neurology (2022).
Rifai OM, Longden J, O’Shaughnessy J, Sewell MDE, Pate J, McDade K, Daniels MJD, Abrahams S, Chandran S, McColl BW, Sibley CR, Gregory JM. Random forest modelling demonstrates microglial and protein misfolding features to be key phenotypic markers in C9orf72-ALS. Journal of Pathology 2022; [see here for associated preprint]
Wong C, Dakin RS, Williamson J, Newton J, Steven M, Colville S, Stavrou M, Gregory JM, Elliott E, Mehta AR, Chataway J, Swingler RJ, Parker RA, Weir CJ, Stallard N, Parmar MKB, Macleod MR, Pal S, Chandran S. Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open 2022; 12: e064173.
Zacco E, Kantelberg O, Milanetti E, Armaos A, Panei FP, Gregory JM, Jeacock K, Chandran S, Clarke D, Ruocco G, Gustincich S, Horrocks M, Pastore A, Tartaglia GG. Probing TDP-43 condensation using an in silico designed aptamer. Nature Communications 2022; 13: 3306.
Wong C, Gregory JM, Liao J, Egan K, Vesterinen HM, Khan AA, Anwar M, Beagan C, Brown F, Cafferkey J, Cardinali A, Chiam JY, Chiang C, Collins V, Dormido J, … and 36 others. A systematic approach to identify neuroprotective interventions for motor neuron disease. medRxiv 2022; 2022.04.13.22273823.
Pattle SB, O’Shaughnessy J, Rifai OM, Pate J, Arends MJ, Waldron FM, Gregory JM. pTDP-43 aggregates accumulate in the gut and other non-central nervous system tissues prior to symptom onset in amyotrophic lateral sclerosis. bioRxiv 2022; 2022.03.17.484805.
Jiwaji Z, Tiwari SS, Avilés-Reyes RX, Hooley M, Hampton D, Torvell M, Johnson DA, McQueen J, Baxter P, Sabari-Sankar K, Qiu J, He X, Fowler J, Febery J, Gregory JM, and 33 others. Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology. Nature Communications 2022; 13(1):135.
Banerjee P, Elliott E, Rifai OM, O’Shaughnessy J, McDade K, Abrahams S, Chandran S, Smith C, Gregory JM. NLRP3 inflammasome as a key molecular target underlying cognitive resilience in amyotrophic lateral sclerosis. Journal of Pathology 2022; 256(3):262-268. [click here for associated invited commentary in Journal of Pathology]
2021
Rifai OM, Longden J, O’Shaughnessy J, Sewell MDE, McDade K, Daniels MJD, Abrahams S, Chandran S, McColl B, Sibley CR, Gregory JM. Random forest modelling of neuropathological features identifies microglial activation as an accurate pathological classifier of C9orf72-related amyotrophic lateral sclerosis. bioRxiv 2021: 2021.12.10.471808
Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, Williams TL, Chataway J, Swingler R, Parmar MKB, Stallard N, Weir CJ, Parker RA, Chaouch A, Hamdalla H, and 24 others. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Communications 2021; 3(4):fcab242.
Ng Kee Kwong KC, Harbham PK, Selvaraj BT, Gregory JM, Pal S, Hardingham GE, Chandran S, Mehta AR. 40 years of CSF toxicity studies in ALS: what have we learnt about ALS pathophysiology? Frontiers in Molecular Neuroscience 2021; 14:647895.
Mehta AR, Gregory JM, Dando O, Carter RN, Burr K, Nanda J, Story D, McDade K, Smith C, Morton NM, Mahad DJ, Hardingham GE, Chandran S, Selvaraj BT. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathologica 2021; 141(2):257-279.
Barton SK, Magnani D, James OG, Livesey MR, Selvaraj BT, James OT, Perkins EM, Gregory JM, Cleary E, Ausems CRM, Carter RNC, Vasistha NA, Zhao C, Burr K, Story D, and 5 others. Transactive response DNA-binding protein-43 proteinopathy in oligodendrocytes revealed using an induced pluripotent stem cell model. Brain Communications 2021; 3(4):fcab255.
Barton SK*, Gregory JM*, Selvaraj BT, McDade K, Henstridge CM, Spires-Jones TL, James OG, Mehta AR, Story D, Burr K, Magnani D, Isaacs AM, Smith C, Chandran S. Dysregulation in subcellular Localization of myelin basic protein mRNA does not result in altered myelination in amyotrophic lateral sclerosis. Frontiers in Neuroscience 2021; 15:705306. *equal contributions
2020
Ng Kee Kwong KC, Gregory JM, Pal S, Chandran S, Mehta AR. Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis: a systematic review of in vitro studies. Brain Communications 2020; 2(2):fcaa121.
Mehta AR, Selvaraj BT, Barton SK, McDade K, Abrahams S, Chandran S, Smith C, Gregory JM. Improved detection of RNA foci in C9orf72 amyotrophic lateral sclerosis post-mortem tissue using BaseScope™ shows a lack of association with cognitive dysfunction. Brain Communications 2020; 2(1):fcaa009.
Gregory JM, McDade K, Livesey MR, Croy I, Marion de Proce S, Aitman T, Chandran S, Smith C. Spatial transcriptomics identifies spatially dysregulated expression of GRM3 and USP47 in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology 2020; 46(5):441-457. [top 10 most downloaded article in Neuropathology and Applied Neurobiology in 12 months following online publication]
Gregory JM, McDade K, Bak TH, Pal S, Chandran S, Smith C, Abrahams S. Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. Journal of Neurology, Neurosurgery and Psychiatry 2020; 91(2):149-157. [click here for associated invited commentary in Journal of Neurology, Neurosurgery and Psychiatry]
Gregory JM, Livesey MR, McDade K, Selvaraj BT, Barton SK, Chandran S, Smith C. Dysregulation of AMPA receptor subunit expression in sporadic ALS post-mortem brain. Journal of Pathology 2020; 250(1):67-78.
Gregory JM, Fagegaltier D, Phatnani H, Harms MB. Genetics of amyotrophic lateral sclerosis. Current Genetic Medicine Reports 2020; 8(4):121-131.
Gregory JM, Elliott E, McDade K, Bak T, Pal S, Chandran S, Abrahams S, Smith C. Neuronal clusterin expression is associated with cognitive protection in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology 2020; 46(3):255-263.
Elliott E, Newton J, Rewaj P, Gregory JM, Tomarelli L, Colville S, Chandran S, Pal S. An epidemiological profile of dysarthria incidence and assistive technology use in the living population of people with MND in Scotland. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2020; 21(1-2):116-122.
Elliott E, Bailey O, Waldron FM, Hardingham GE, Chandran S, Gregory JM. Therapeutic targeting of proteostasis in amyotrophic lateral sclerosis – a systematic review and meta-analysis of preclinical research. Frontiers in Neuroscience 2020; 14:511.
2019
Mehta AR, Walters R, Waldron FM, Pal S, Selvaraj BT, Macleod MR, Hardingham GE, Chandran S, Gregory JM. Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Brain Communications 2019; 1(1):fcz009.
Barton SK, Gregory JM, Chandran S, Turner BJ. Could an impairment in local translation of mRNAs in glia be contributing to pathogenesis in ALS? Frontiers in Molecular Neuroscience 2019; 12:124.
2018
Selvaraj BT, Livesey MR, Zhao C, Gregory JM, James OT, Cleary EM, Chouhan AK, Gane AB, Perkins EM, Dando O, Lillico SG, Lee YB, Nishimura AL, Poreci U, Thankamony S, and 17 others. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca(2+)-permeable AMPA receptor-mediated excitotoxicity. Nature Communications 2018; 9(1):347.
Majumder V*, Gregory JM*, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurology 2018; 18(1):90. *equal contributions
2017
Gregory JM, Whiten DR, Brown RA, Barros TP, Kumita JR, Yerbury JJ, Satapathy S, McDade K, Smith C, Luheshi LM, Dobson CM, Wilson MR. Clusterin protects neurons against intracellular proteotoxicity. Acta Neuropathologica Communications 2017; 5(1):81
2016
Gregory JM, Waldron FM, Soane T, Fulton L, Leighton D, Chataway J, Pal S, Chandran S, Macleod MR. Protocol for a systematic review and meta-analysis of experimental models of amyotrophic lateral sclerosis. Evidence-based Preclinical Medicine 2016; 3(2):e00023.
Crippa V, Cicardi ME, Ramesh N, Seguin SJ, Ganassi M, Bigi I, Diacci C, Zelotti E, Baratashvili M, Gregory JM, Dobson CM, Cereda C, Pandey UB, Poletti A, Carra S. The chaperone HSPB8 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity. Human Molecular Genetics 2016; 25(18):3908-3924.
2012
Gregory JM, Barros TP, Meehan S, Dobson CM, Luheshi LM. The aggregation and neurotoxicity of TDP-43 and its ALS-associated 25 kDa fragment are differentially affected by molecular chaperones in Drosophila. PLoS One 2012; 7(2):e31899.